BridgeBio's Calcilytix Sees POC For Encaleret And Options To Discuss With FDA
Company Presents Early Phase II Data At ENDO
Executive Summary
Calcilytix chief medical officer Jonathan Fox talked to Scrip about the development plans for encaleret for the rare form of hypoparathyroidism.
You may also be interested in...
BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.
SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.